This report was first published by Endpoints News. To see the original version, click here
China’s new commercial insurance formulary looks to expand patient access to Alzheimer’s disease medicines from Eli Lilly and Eisai while potentially boosting revenue for the companies.
Announced in December, the Commercial Health Insurance Innovative Drug List is designed to cover advanced therapies that fall outside basic government insurance. For drugmakers, the list has the potential to bolster bottom lines, though it is unclear if, or how quickly, Chinese commercial health insurers are going to cover these medicines.
您已阅读23%（616字），剩余77%（2016字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。